Hot
- +1 609-736-0910
- info@alphalifetech.com
- 90 State Street, STE 700 Office 40, Albany, NY 12207 United States
Product Background
Catalog Number |
ADT1054 |
Product Name |
ADT1054-Atezolizumab Biosimilar– Anti-CD274, B7-H1, PDL1 mAb – Research Grade |
Alias |
MPDL3280A, RG7446 |
Isotype |
IgG1 Kappa |
Clonity |
Monoclonal |
|
Alternate Names cd274 gene, pd-l1 gene, pd-l1 antibody, human pd-l1 antibody, mouse pd-l1, human cd274, recombinant cd274, Atezolizumab Biosimilar
|
|
Official Symbol |
CD274/B7-H1/PDL1 |
Species |
Human |
Expression Host |
CHO Cells |
Reactivity |
Human |
Gene ID |
29126 |
CAS Number |
1380723-44-3 |
Molecular Weight |
144.59 KDa |
Product Description |
Atezolizumab, sold under the brand name Tecentriq, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and hepatocellular carcinoma (HCC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). |
Mechanism of Action |
Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes Inhibitionition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. |
Metabolism |
Monoclonal antibodies are broken down into smaller polypeptides and amino acids. |
Size |
1mg,5mg |
Research Area |
Cancer |
Application |
ELISA, IHC, IF, IP, Flow Cytometry |
Purity |
>95% as determined by SDS-PAGE |
Concentration |
Batch dependent |
Buffer |
Supplied in PBS, PH7.5 |
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
Shipping Condition |
Shipped on ice packs. |
Note |
This product is for research use only. |
|
Reference 1.Tian X, et al. Biomolecules, 2023 Jun 15. PMID 37371571
2.Kubes V, et al. In Vivo, 2023 Jul-Aug. PMID 37369476
3.Adiputra PAT, et al. Asian Pac J Cancer Prev, 2023 May 1. PMID 37247264
|
FAQ
-
+ -
What is a biosimilar?
A biosimilar is a biological product that is highly similar to an existing approved reference biological product (also known as the originator or reference product), with no clinically meaningful differences in terms of safety, purity, and potency. Biosimilars are developed to be highly similar to the reference product in terms of structure, function, pharmacokinetics, and clinical efficacy. Alpha Lifetech can provide biosimilar antibody products.
-
+ -
How can I obtain COA of the reagent that I received?
Please contact us via email info@alphalifetech.com for detailed information about the product.
-
+ -
Why choose Alpha Lifetech’s product?
Alpha Lifetech's products are chosen for their quality, reliability, and competitive pricing. Our biosimilar antibodies undergo thorough development and testing processes to ensure they meet regulatory requirements and deliver comparable performance to reference products. We prioritize customer satisfaction and strive to provide cost-effective solutions without compromising on quality. -
+ -
How to purify your antibodies?
Protein A/G Chromatography: Protein A and Protein G are affinity chromatography matrices that specifically bind to the Fc region of antibodies, allowing for their purification from complex mixtures.
Ion Exchange Chromatography: Ion exchange chromatography separates proteins based on their net charge at a specific pH.
Size Exclusion Chromatography: Size exclusion chromatography (SEC), also known as gel filtration chromatography, separates proteins based on their size and shape.
Affinity Tag Purification: Some recombinant antibodies are engineered with affinity tags (e.g., His-tag, FLAG-tag) that facilitate purification. Affinity tag purification involves using specific affinity resins or columns that bind to the tag, allowing for purification of the tagged antibodies. Alpha Lifetech has multiple antibody purification strategies. Please contact us via email info@alphalifetech.com for more detailed information.